• Citer

Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial).

par Cornely, Oliver A;Maertens, J.;Bresnik, Mark;Ebrahimi, Ramin;Ullmann, Andrew;Bouza, Emilio;Heussel, Claus Peter;Lortholary, Olivier;Rieger, Christina;Boehme, Angelika;Aoun, Michel ;Horst, Heinz-August;Thiebaut, Anne;Ruhnke, Markus;Reichert, Dietmar;Vianelli, Nicola;Krause, Stefan W;Olavarria, Eduardo;Herbrecht, R;AmBiLoad Trial Study Group,
Référence Clinical infectious diseases, 44, 10, page (1289-1297)
Publication Publié, 2007-05

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

Treatment of invasive mold infection in immunocompromised patients remains challenging. Voriconazole has been shown to have efficacy and survival benefits over amphotericin B deoxycholate, but its utility is limited by drug interactions. Liposomal amphotericin B achieves maximum plasma levels at a dosage of 10 mg/kg per day, but clinical efficacy data for higher doses are lacking.